Bristol won't seek faster Opdivo/Yervoy lung cancer approval

(Reuters) - Bristol-Myers Squibb Co on Thursday said it has decided not to seek accelerated U.S. approval for a combination of its two immunotherapy drugs as an initial treatment for lung cancer.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news